<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181112</url>
  </required_header>
  <id_info>
    <org_study_id>H19-00782 FMT.MDRO.RCT.1</org_study_id>
    <nct_id>NCT04181112</nct_id>
  </id_info>
  <brief_title>Fecal Transplant for MDRO Decolonization</brief_title>
  <official_title>Fecal Microbiota Transplantation (FMT) for Intestinal Decolonization of Multidrug-resistant Opportunistic Pathogens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial designed to determine whether fecal microbiota transplantation (FMT) can&#xD;
      eliminate highly drug-resistant bacteria from the intestinal tract of renal transplant&#xD;
      patients. The primary goal of this study is to test whether oral gut decontamination followed&#xD;
      by FMT using enema delivery will result in decolonization of the intestinal tract of renal&#xD;
      transplant patients shortly after solid organ transplantation, thereby preventing difficult&#xD;
      to treat post-transplant infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Contact the study principal investigator for the study protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The elimination of the target multi-drug resistant organism (MDRO), using culture and molecular test-based screening of recipient stool, at both the 14 and 30 days post-FMT.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare proportions, type and timing of adverse events post-FMT</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of recolonization over 180 days</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing of recolonization over 180 days</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Multi-antibiotic Resistance</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation with antibiotic pre-treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation (FMT)</intervention_name>
    <description>FMT using retention enema</description>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <arm_group_label>Fecal microbiota transplantation with antibiotic pre-treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Renal transplant patient inclusion criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Positive for one of the target MDRO by rectal or stool culture tests&#xD;
&#xD;
        FMT stool donor inclusion criteria:&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Able to complete donor screening&#xD;
&#xD;
          -  Able to adhere to FMT stool collection and testing procedures&#xD;
&#xD;
        Renal transplant patient exclusion criteria:&#xD;
&#xD;
          -  Still in hospital at week 7 following organ transplantation&#xD;
&#xD;
          -  Pregnant or planning to become pregnant&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Participating in another interventional or investigational study&#xD;
&#xD;
          -  Neutropenic (ANC &lt; 0.5)&#xD;
&#xD;
          -  Presence of colostomy or ileostomy&#xD;
&#xD;
          -  Has an active intestinal infection&#xD;
&#xD;
          -  Fever &gt; 38.0 or white blood count (WBC) count &gt; 15,000&#xD;
&#xD;
          -  Are taking a non-dietary probiotic supplement&#xD;
&#xD;
          -  Require or are expected to require systemic antimicrobial therapy other than&#xD;
             Pneumocystis prophylaxis or cytomegalovirus (CMV) therapy during the study period&#xD;
&#xD;
          -  Has a severe underlying disease with anticipated survival less than 6 months&#xD;
&#xD;
          -  Are unable to tolerate FMT or enema for any reason, or where their physician believes&#xD;
             for any reason that FMT might pose a health risk to the subject&#xD;
&#xD;
          -  Subjects who report a history of anaphylactoid food allergy will not be excluded but&#xD;
             these allergies will be noted and donors will be required to avoid ingestion of these&#xD;
             foods for at least three days prior to donation&#xD;
&#xD;
        FMT stool donor exclusion criteria:&#xD;
&#xD;
          -  Presence of any of the following by stool examination: vancomycin-resistant&#xD;
             Enterococci (VRE), Salmonella, Shigella, shiga toxin-producing E. coli, Yersinia,&#xD;
             Campylobacter, extended spectrum beta-lactamase (ESBL) producing organisms or&#xD;
             carbapenemase-producing Enterobacteriaceae (CRE), pathogenic ova or parasites, C.&#xD;
             difficile toxin B (by PCR), or rotavirus, adenovirus and norovirus&#xD;
&#xD;
          -  History of any type of active cancer aside from melanoma&#xD;
&#xD;
          -  Risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C, prion or any&#xD;
             neurological disease as determined by the donor questionnaire&#xD;
&#xD;
          -  History of gastrointestinal comorbidities, e.g., inflammatory bowel disease, irritable&#xD;
             bowel syndrome, chronic constipation or diarrhea, or colostomy or ileostomy&#xD;
&#xD;
          -  Receipt of blood transfusion from a country other than Canada in the preceding 6&#xD;
             months&#xD;
&#xD;
          -  Antibiotic use or any systemic immunosuppressive agents in the 3 months prior to stool&#xD;
             donation&#xD;
&#xD;
          -  Receipt of any live vaccine within 3 months prior to stool donation&#xD;
&#xD;
          -  Any current or previous medical or psychosocial condition or behaviors which in the&#xD;
             opinion of the investigator may pose risk to the recipients or the donor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amee Manges, MPH, PhD</last_name>
    <phone>604 707 2743</phone>
    <email>amee.manges@ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence Health Care - St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver Coastal Health - Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Steiner, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Amee Manges</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

